Vorsetuzumab

• CAT Number: I042434
• CAS Number: 1165740-62-4
• Molecular Weight: 146.1 (kDa)
• Purity: ≥95%

Vorsetuzumab (Cat No.: I042434) is a humanized monoclonal antibody developed to target CD70, a tumor necrosis factor (TNF) family ligand overexpressed in various cancers, including renal cell carcinoma and hematologic malignancies. By binding to CD70, vorsetuzumab disrupts CD70-CD27 signaling, which plays a role in tumor cell proliferation, survival, and immune evasion. It may also facilitate antibody-dependent cellular cytotoxicity (ADCC). Vorsetuzumab has been investigated as both a naked antibody and as an antibody-drug conjugate (ADC), offering potential for targeted cancer therapy with enhanced specificity.

Reference

[1]. Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585.
[Content Brief]